BRAIN Biotech is a German biotechnology company specializing in enzyme discovery, biocatalysis, and microbial strain development for industrial applications in pharmaceuticals, food, and sustainability.
What are the typical clients of BRAIN Biotech?
BRAIN Biotech operates in the life sciences sector, offering specialized enzyme solutions. A key component of our work is the MetXtra technology, introduced last summer. This initiative focuses on discovering and providing novel enzymes that function as biocatalysts, transforming substrates into APIs in a more sustainable way. Traditional chemical synthesis often requires high temperatures and pressures and results in racemic mixtures where half the product may be unusable. Our enzymes optimize efficiency and sustainability in this process.
We collaborate extensively with the pharmaceutical industry, particularly companies involved in biocatalysis. Among the top 20 global pharmaceutical firms, we are in active discussions or collaborations with about two-thirds of them. While decades ago, we would have primarily worked with German companies, the pharma landscape has shifted. Today, most major players are in the US, the UK, and Switzerland, with generics production also thriving in India and China. We have adapted to this evolution, ensuring our solutions remain globally relevant.
The US funding environment is very different from Europe’s, and competition in enzyme production is strong. How does BRAIN differentiate itself from competitors there?
One of our key advantages is our proprietary MetXtra enzyme library, which contains a wealth of genetic data not accessible to competitors. This exclusivity allows our partners to identify novel enzymes and secure strong intellectual property positions in previously unexplored sequence spaces. This is a major draw for companies looking to build competitive advantages in biocatalysis.
Additionally, our expertise in production hosts sets us apart. Many competitors specialize in just one microbial system—E. coli, yeast, or bacillus—whereas we can tailor the right production host to a given enzyme. Our advanced genome editing capabilities, developed in-house and outside the scope of CRISPR patents held by Broad Institute and others, allow us to optimize strains for efficiency. This combination of proprietary enzyme discovery, flexible production systems, and unique genome editing technologies makes us a compelling partner.
Germany was once known as the "pharmacy of the world." Is it challenging to operate and manufacture in Germany of today, as the economy is struggling on multiple fronts?
Not necessarily, as long as we do not limit ourselves to Germany. Three decades ago, roughly 80% of our collaborations were with German companies. Today, that number is closer to 20%. To stay competitive, we have expanded our reach, working with partners in North America, Asia, and South America.
For example, in Brazil, there is significant development in bioethanol and food-related industries, presenting exciting collaboration opportunities. Growth is happening worldwide, and we are well-positioned to engage with companies across different regions. The key is to maintain a global outlook rather than relying solely on the domestic market.
What are BRAIN Biotech’s plans for the future? How do you see the company evolving in the next few years?
As part of BRAIN Group, we have a clear five-year strategy with ambitious growth plans. We operate in three main areas, with our largest segment being the sale of enzymes for food, technical, and feed markets. These enzymes help optimize products in industries like baking, dairy, and beverages. This segment accounts for about 70% of our current revenue, and we aim to double it in the next five years.
My division focuses on research collaborations. We provide access to our technology for partners, charging tech access fees, research costs, milestone payments, and royalties when products reach the market. This area ensures stable revenue and helps bring long-term partners into our ecosystem. Through these collaborations, we can identify new commercial opportunities, further strengthening BRAIN’s position in the enzyme industry.
Finally, why should our readers follow the story of BRAIN Biotech?
BRAIN Biotech has a 30-year track record of delivering results. We have built a reputation for reliability, creativity, and scientific excellence. Clients trust us because we solve complex problems and have successfully completed over 200 collaborations. We always find a way to make projects work, even if the original question needs refinement along the way.
From an investment perspective, BRAIN represents a strong growth opportunity. Currently, we hold just 0.2% of the global enzyme market—meaning there is immense room for expansion. Not many companies can realistically aim to double their revenue within five years, but we can. While each investor must make their own decision, I personally believe in the company’s future, and I continue to invest in BRAIN’s shares myself.
